

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – December 8, 2020



WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

(State or other jurisdiction  
of incorporation)

1-8036

(Commission File Number)

23-1210010

(IRS Employer  
Identification No.)

530 Herman O. West Drive, Exton, PA

(Address of principal executive offices)

19341-0645

(Zip Code)

Registrant's telephone number, including area code: **610-594-2900**

Not Applicable

(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$0.25 per share	WST	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On December 9, 2020, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that its Board of Directors (the “Board”) approved a first-quarter 2021 dividend of \$0.17 per share. The dividend will be paid on February 3, 2021, to shareholders of record as of January 20, 2021.

On January 13, 2021, the Company will present an overview of its business at the J.P. Morgan Healthcare Conference at 5:20 PM Eastern Standard Time.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

**Item 8.01 Other Events.**

On December 8, 2020, the Company's Board authorized a share repurchase program for calendar-year 2021 of up to 631,000 shares of the Company's common stock from time to time on the open market or in privately-negotiated transactions, as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The share repurchase program is expected to be completed by December 31, 2021. The Company's previously-authorized share repurchase program will expire on December 31, 2020.

**Item 9.01 Financial Statements and Exhibits.**

(d)	<u>Exhibit No.</u>	<u>Description</u>
	99.1	West Pharmaceutical Services, Inc. Press Release, dated December 9, 2020.
	104	The cover page from the Company’s Current Report on Form 8-K, dated December 8, 2020, formatted in Inline XBRL.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ Bernard J. Birkett

Bernard J. Birkett

Senior Vice President and Chief Financial Officer

December 9, 2020

## EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">West Pharmaceutical Services, Inc. Press Release, dated December 9, 2020.</a>
104	The cover page from the Company's Current Report on Form 8-K, dated December 8, 2020, formatted in Inline XBRL.



Exhibit 99.1

**Investor Contact:**

Quintin Lai  
Vice President, Investor Relations  
+1-610-594-3318  
[Quintin.Lai@westpharma.com](mailto:Quintin.Lai@westpharma.com)

**Media Contact:**

Michele Pelkowski  
Vice President, Global Communications  
+1-610-594-3054  
[Michele.Pelkowski@westpharma.com](mailto:Michele.Pelkowski@westpharma.com)

**West Announces First-Quarter 2021 Dividend, 2021 Share Repurchase Program and Participation in Upcoming Investor Conference**

**Exton, PA, December 9, 2020** — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2021 dividend of \$0.17 per share. The dividend will be paid on February 3, 2021, to shareholders of record as of January 20, 2021.

On December 8, 2020, the Company's Board of Directors authorized a share repurchase program for calendar-year 2021 of up to 631,000 shares of the Company's common stock from time to time on the open market or in privately-negotiated transactions, as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The share repurchase program is expected to be completed by December 31, 2021. The Company's previously-authorized share repurchase program will expire on December 31, 2020.

The Company also announced that management will be presenting an overview of the business at the J.P. Morgan Healthcare Conference at 5:20 p.m. EST on Wednesday, January 13, 2021. A live audio webcast of the presentations and a copy of the presentation materials will be accessible from the Company's website at [www.westpharma.com/en/investors](http://www.westpharma.com/en/investors).

**About West**

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2019 sales of \$1.84 billion reflect the daily use of more than 100 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

*All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.*